kidney yang deficiency syndrom
Conditions
Interventions
Trial Group 2:Experimental medication regime combined with lifestyle guidance. The regime: Jingui-Shenqi Pill was given orally once a day, 2 pills each time. Administration time: Half an hour after di
Control group 2:Experimental medication regime combined with lifestyle guidance. The regime: Jingui-Shenqi Pill was given orally twice a day, 1 pill each time. Administration time: Half an hour after
Control group 1:Experimental medication regime combined with lifestyle guidance. The regime: Guifu-Dihuang pill was taken orally twice a day, 1 pill each time. Administration time: Half an hour after
Trial Group 1:Experimental medication regime combined with lifestyle guidance. The regime: Guifu-Dihuang pill was taken orally once a day, 2 pills each time. Administration time: Half an hour after di
Develop good sleep habits
Stay warm at night
Moderate exercise.
Sponsors
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
55 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Informed consent was obtained from the subjects or their legal guardians; (2) Age 55-75 years old (including the cut-off value) regardless of gender; (3) Meet the diagnostic criteria of kidney Yang deficiency syndrome of TCM; (4) Frequent nocturia at the time of screening. (5) Patients could accept lifestyle management and correctly use the smart urine meter during the study.
Exclusion criteria
Exclusion criteria: (1) Individuals with allergic constitution (two or more allergies to drugs food or the environment) or known allergies to experimental drugs and their components; (2) Patients with acute infectious diseases (course 37.5?); (3) Subjects who received medication treatment within one week that had a clear impact on NP and were deemed unsuitable for discontinuation by the researchers (If the stabilizer dosage is maintained during the trial period participants can be included in this trial); (4) There are clear surgical indications during screening which indicates the necessity of undergoing surgical treatment in the near future by the researcher's estimate; (5) When screening the primary diseases in patients are in the acute progressive or unstable phases and the patients are not suitable for long-term treatment with investigational drugs such as urinary system tumors trauma severe sleep apnea syndrome and severe congestive heart failure causing NP; (6) Patients who have combined other serious respiratory digestive blood cardiovascular endocrine and urinary system diseases and are deemed unsuitable for treatment with the investigational drug by the researchers; (7) Patients with combined neurological and psychiatric disorders who according to the researcher's estimate find it difficult to complete self-assessment; (8) Individuals who have participated in other clinical trials within three months; (9) Patients with false fire floating syndrome symptoms include swelling and pain in the throat sores in the mouth and tongue body heat and irritability swollen and painful gums dry stools redness and lack of saliva in the tongue etc; (10) Other situations that the researchers believe are not suitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nocturia frequency of urination; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete remission rate of nocturnal urination;nocturnal urinevolume;time to onset; | — |
Countries
China
Contacts
Public ContactTang Jianyuan
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed